Contineum Therapeutics (CTNM) Research & Development (2023 - 2026)

Contineum Therapeutics' Research & Development history runs 4 years deep, the most recent figure standing at $12.7 million for Q2 2026.

• In Q2 2026, Research & Development fell 9.68% year-over-year to $12.7 million; the TTM figure through Jun 2026 stood at $48.1 million (down 4.79% YoY), while the FY2025 annual figure was $51.5 million, up 34.1% from the prior year.
• Research & Development for Q2 2026 stood at $12.7 million, up from $11.6 million in the prior quarter.
• The five-year high for Research & Development was $14.1 million in Q2 2025, with the low at $3.6 million in Q1 2023.
• The 4-year median for Research & Development is $10.4 million (2024), against an average of $10.1 million.
• Peak annual rise in Research & Development reached 114.15% in 2024, while the deepest fall reached 16.48% in 2024.
• Contineum Therapeutics' Research & Development stood at $8.0 million in 2023, then surged by 62.44% to $13.0 million in 2024, then declined by 2.0% to $12.8 million in 2025, then slipped by 0.42% to $12.7 million in 2026.
• Business Quant data shows CTNM's Research & Development at $12.7 million in Q2 2026, $11.6 million in Q1 2026, and $12.8 million in Q4 2025.